UK – Angle, a UK based liquid biopsy company,has entered a supplier agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay tailored for prostate cancer studies. 

Angle will spearhead the assay’s development in its UK laboratories, under the terms of the agreement valued at £550,000 (US$ 695,767). 

This development is expected to significantly impact cancer research and therapy efficacy assessment.

The Parsotix system, developed by Angle, specializes in capturing and harvesting circulating tumor cells (CTCs) from blood samples, facilitating downstream analysis.

Androgen Receptor (AR) assays focus on a nuclear protein crucial for cell growth, cycle progression, protein synthesis, and cell death, making it a vital marker in cancer research and treatment effectiveness evaluation.

This partnership signifies an expansion of a previous collaboration aimed at developing a methodology for detecting CTC micronuclei using Angle’s DNA Damage Response (DDR) assay.

Angle’s CEO, Andrew Newland, emphasized the significance of this collaboration, stating, “This is further validation of Angle’s Parsortix system, which shows potential for long-term large-scale revenues in bringing innovative new cancer drugs to the market.” 

Newland anticipates that the success of the assay’s initial development phase could lead to broader contracts for its application in clinical trials, underscoring its potential impact on cancer therapeutics.

Additionally, Angle’s chief scientific officer, Karen Miller, highlighted the broader implications of the new androgen receptor assay, noting, “The new androgen receptor assay will also be an important addition to the menu of assays we can offer other customers.”

Angle’s history of assay development includes its Portrait Flex CTC assay, which has advanced personalized cancer care. 

Furthermore, recent strides in patent approvals underscore the company’s commitment to innovation. 

The European Patent Office (EPO) recently granted a European patent for Angle’s CellKeep slide, aimed at enhancing the capture of CTCs. 

Concurrently, the United States Patent and Trademark Office (USPTO) signaled the imminent grant of its equivalent US patent application.

The urgency to develop effective diagnostic and therapeutic tools for prostate cancer is underscored by projections from the International Agency for Research on Cancer. 

The agency estimates that by 2040, annual prostate cancer-related deaths could surpass 700,000, highlighting the critical need for early detection and appropriate treatment strategies.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook